cjc-1295 & ipamorelin uae | research peptide guide | bodypharm uae.

CJC-1295 Ipamorelin UAE researchers now have access to a pharmaceutical grade dual-peptide formulation through BodyPharm UAE. CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) and Ipamorelin is a selective growth hormone secretagogue. Supplied together as a 10mg/10mg blend, the CJC-1295 Ipamorelin UAE combination is one of the most studied dual-peptide systems in growth hormone axis research.

Laboratories investigating pituitary biology, growth hormone pulsatility, and downstream anabolic signalling use the CJC-1295 Ipamorelin UAE formulation as a research tool for probing complementary receptor pathways in a single experimental context.

CJC-1295 (also known as DAC:GRF) is a modified GHRH analogue designed to extend the half-life of the native GHRH peptide through albumin-binding chemistry. The Drug Affinity Complex (DAC) modification confers extended plasma stability compared to native GHRH, enabling sustained receptor engagement in experimental models.

Studies indicate that CJC-1295 stimulates growth hormone release from anterior pituitary somatotroph cells via the GHRH receptor (GHRHR). Published research has characterised dose-dependent increases in circulating growth hormone and IGF-1 in human subjects in Phase 1/2 studies, establishing the compound's pharmacodynamic profile in the peer-reviewed literature.

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a), a distinct receptor pathway from the GHRH receptor targeted by CJC-1295. Research indicates that ipamorelin produces growth hormone release with high selectivity relative to other pituitary hormones such as cortisol and prolactin, a characteristic that has made it a frequently studied growth hormone secretagogue in research settings.

Preliminary findings from preclinical and early clinical research suggest that ipamorelin's selectivity profile makes it a useful tool for isolating growth hormone secretagogue effects without the confounding hormonal responses observed with less selective GHS-R agonists.

The CJC-1295 Ipamorelin UAE combination engages two distinct receptor pathways in the growth hormone axis simultaneously. CJC-1295 acts at the GHRH receptor to stimulate GH release, while ipamorelin acts at the ghrelin receptor (GHS-R1a) to augment GH secretion through a separate signalling cascade.

Research suggests the combination produces synergistic GH release compared to either compound used in isolation, as the two receptor pathways converge on pituitary somatotroph function through different intracellular mechanisms. This dual engagement model is the primary research rationale for the combined formulation used in CJC-1295 Ipamorelin UAE laboratory studies.

BodyPharm UAE supplies CJC-1295 Ipamorelin UAE as a lyophilised 10mg/10mg dual-peptide formulation. Each batch is independently verified for purity and supplied with a Certificate of Analysis confirming peptide identity by mass spectrometry and purity by HPLC. Same-day delivery is available across Dubai, Abu Dhabi, Sharjah, and the wider UAE.

Procurement criteria for CJC-1295 Ipamorelin UAE research supply should include:

• Separate HPLC purity verification for each peptide component
• Mass spectrometry confirmation of both molecular weights
• Batch-specific Certificates of Analysis
• Research-use-only supply terms

Store lyophilised CJC-1295 Ipamorelin UAE vials at 2-8 degrees Celsius, protected from light and moisture. Reconstitute using bacteriostatic water, adding the liquid slowly and swirling gently to avoid foaming. Use reconstituted solution within standard peptide stability windows. Do not freeze reconstituted solution.

BodyPharm UAE supplies CJC-1295 & Ipamorelin 20mg for research use with same-day delivery across Dubai. View the complete research peptide catalogue for all available compounds.

BodyPharm products are sold strictly for research purposes only and are not intended for human consumption, diagnosis, or treatment.